Graph AI, a California-based AI life sciences startup, has raised $3 million in seed funding led by Bessemer Venture Partners. The investment will accelerate the development and global adoption of Graph Safety, an AI-native platform designed to automate adverse drug event (ADE) monitoring, regulatory submissions, and safety intelligence aggregation for pharmaceutical and biotech companies.
Glimpse:
Graph AI’s platform, Graph Safety, offers a unified AI-native safety stack that combines data integration, intelligent automation, and end-to-end auditability. Early enterprise deployments have shown up to 70% efficiency gains, 90% faster regulatory reporting, and significant cost savings while maintaining traceability. The platform currently spans more than 7,000 marketed drugs, reflecting growing demand for scalable automation solutions in drug safety.
Graph AI, a California-based AI life sciences startup, has raised $3 million in seed funding led by Bessemer Venture Partners to accelerate innovation, grow its engineering team, and expand globally. Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, the company is focused on transforming how pharmaceutical firms detect and report adverse drug events (ADEs).
Its flagship platform, Graph Safety, leverages context-aware AI to automate complex pharmacovigilance tasks such as case processing, signal detection, and regulatory reporting—while maintaining human oversight for critical review steps. This human-in-the-loop design helps teams shift from repetitive data work to strategic decision-making.
Early enterprise results show remarkable efficiency gains up to 70% faster operations, 90% quicker reporting, and major cost reductions without compromising accuracy or compliance. The platform already supports more than 7,000 marketed drugs, highlighting its scalability and growing market demand.
With a compliance-first and transparent approach, Graph AI ensures every regulatory-critical step remains auditable and version-controlled. The new funding will help the company strengthen its platform and expand into the $8 billion global pharmacovigilance market, driving the future of AI-powered drug safety.
“We’re excited to partner with Graph AI as they redefine labor-intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize both accuracy and scalability.”
By
HB Team
